Ulcer
Drug research and approvals for ulcer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 557 studies of ulcer are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 557
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 2
Recruiting Now
Newest start dates first, of 557 recruiting on ClinicalTrials.gov ↗- A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With…NCT07846683 · Phase 3 · Hoffmann-La Roche · starts Nov 15, 2026
- Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related DisordersNCT07683104 · Not reported · National Institute of Allergy and Infectious Diseases (NIAID) · starts Nov 10, 2026
- Longitudinal Immunophenotyping of Patients With Inflammatory Bowel DiseaseNCT07619547 · Not reported · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · starts Nov 5, 2026
- Microbiome-targeted Diet Therapy in Ulcerative ColitisNCT07520461 · Not applicable · University of Minnesota · starts Nov 4, 2026
- Oral Care Program for Mouth Side Effects During Head and Neck Radiation TherapyNCT07885033 · Not applicable · UNCANCER LLC · starts Nov 1, 2026
- PPI Dosing Per CYP2C19 GenotypeNCT07843264 · Phase 4 · University of Florida · starts Nov 1, 2026
- Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal InflammationNCT07501078 · Phase 2 · Muhammad N Aslam, MD · starts Nov 1, 2026
- Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative ColitisNCT07820046 · Phase 2 / Phase 3 · Tanta University · starts Oct 25, 2026
- Systemic Biochemical Signature and Functional Quality Index of Calcaneal Bone Marrow Aspirate in Adults Undergoing Foot…NCT07802106 · Not reported · Universidade Sao Francisco · starts Oct 21, 2026
- Vacuum Compression Therapy and Tissue Oxygenation in Chronic Leg UlcersNCT07901517 · Not applicable · BTL Industries Ltd. · starts Oct 15, 2026
Drug Pipeline
4 approved, 7 in phase 3, 4 in phase 2, 1 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Famotidine, Collagenase clostridium histolyticum, Ranitidine, Dimethicone
- Macitentan
- Phase 3 Endothelin receptor, ET-A/ET-B antagonist
- Esomeprazole
- Phase 3 Potassium-transporting ATPase inhibitor
- Bosentan
- Phase 3 Endothelin receptor, ET-A/ET-B antagonist
- Cimetidine
- Phase 3 Histamine H2 receptor antagonist
- Pantoprazole
- Phase 3 Potassium-transporting ATPase inhibitor
- Becaplermin
- Phase 3 Platelet-derived growth factor receptor agonist
- Oxygen
- Phase 3 Essential for cellular homeostasis
- Isoniazid
- Phase 2 Enoyl-[acyl-carrier-protein] reductase inhibitor
- Onabotulinumtoxina
- Phase 2 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Riociguat
- Phase 2 Soluble guanylate cyclase positive allosteric modulator
- Omeprazole
- Phase 2 Potassium-transporting ATPase inhibitor
- Aspirin
- Phase 1 Cyclooxygenase inhibitor
How Its Trials Ended
2,313 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 625 whose ending is known, 37% met their primary endpoint, 5% missed it and 57% stopped early.
- Completed, result not reported91339%
- Ongoing45720%
- Status unknown31814%
- Met its primary endpoint23210%
- Stopped: other or unclear1607%
- Stopped: enrollment or feasibility954%
- Stopped: sponsor or business decision593%
- Missed its primary endpoint341%
- Stopped: lack of efficacy321%
- Stopped: funding90%
- Stopped: safety40%
FDA Orphan Designations
Approved first, then open designations, newest first| Jan 13, 2021 | TelacebecTreatment of Buruli ulcer | The Global Alliance for TB Drug Development, Inc. | Designated |
| Aug 1, 1991 | Cyclosporine 2% ophthalmic ointmentFor use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer | Allergan, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Jul 6, 2017 | OxervateCenegermin · orphan | Dompe' Farmaceutici S.p.A. | EMA ↗ |
| Aug 14, 1997 | Helicobacter Test INFAI13C-urea | INFAI, Institut für biomedizinische Analytik NMR-Imaging GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA